WO2001030335A3 - Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease - Google Patents

Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease Download PDF

Info

Publication number
WO2001030335A3
WO2001030335A3 PCT/US2000/041436 US0041436W WO0130335A3 WO 2001030335 A3 WO2001030335 A3 WO 2001030335A3 US 0041436 W US0041436 W US 0041436W WO 0130335 A3 WO0130335 A3 WO 0130335A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
amyloid protein
induced disease
treatment
pharmaceutical compositions
Prior art date
Application number
PCT/US2000/041436
Other languages
French (fr)
Other versions
WO2001030335A2 (en
Inventor
Darrick S H L Kim
Original Assignee
Univ Illinois
Darrick S H L Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Darrick S H L Kim filed Critical Univ Illinois
Priority to AU23000/01A priority Critical patent/AU2300001A/en
Priority to US10/111,039 priority patent/US6887898B1/en
Publication of WO2001030335A2 publication Critical patent/WO2001030335A2/en
Publication of WO2001030335A3 publication Critical patent/WO2001030335A3/en
Priority to US11/084,316 priority patent/US7282523B2/en
Priority to US11/128,638 priority patent/US7279501B2/en
Priority to US11/287,080 priority patent/US7728043B2/en
Priority to US11/872,563 priority patent/US7572829B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C07C49/248—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/233—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/233—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C49/235—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers

Abstract

The invention provides methods for treating beta-Amyloid protein-induced disease, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural product compounds isolated from turmeric, gingko biloba, and ginger, and synthetic chemical analogues thereof, for the treatment of a beta-Amyloid protein-induced disease.
PCT/US2000/041436 1999-10-22 2000-10-23 Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease WO2001030335A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU23000/01A AU2300001A (en) 1999-10-22 2000-10-23 Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
US10/111,039 US6887898B1 (en) 1999-10-22 2000-10-23 Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease
US11/084,316 US7282523B2 (en) 1999-10-22 2005-03-18 Pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease
US11/128,638 US7279501B2 (en) 1999-10-22 2005-05-13 Pharmaceutical composition useful in prevention and treatment of beta-amyloid protein-induced disease
US11/287,080 US7728043B2 (en) 1999-10-22 2005-11-23 Methods for treatment of beta-amyloid protein-induced ocular disease
US11/872,563 US7572829B2 (en) 1999-10-22 2007-10-15 Pharmaceutical compositions useful in prevention and treatment of Beta-amyloid protein-induced disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16114599P 1999-10-22 1999-10-22
US60/161,145 1999-10-22

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10111039 A-371-Of-International 2000-10-23
US11/084,316 Continuation US7282523B2 (en) 1999-10-22 2005-03-18 Pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease
US11/872,563 Division US7572829B2 (en) 1999-10-22 2007-10-15 Pharmaceutical compositions useful in prevention and treatment of Beta-amyloid protein-induced disease

Publications (2)

Publication Number Publication Date
WO2001030335A2 WO2001030335A2 (en) 2001-05-03
WO2001030335A3 true WO2001030335A3 (en) 2002-06-13

Family

ID=22580001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/041436 WO2001030335A2 (en) 1999-10-22 2000-10-23 Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease

Country Status (2)

Country Link
AU (1) AU2300001A (en)
WO (1) WO2001030335A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257428B2 (en) * 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US7728043B2 (en) 1999-10-22 2010-06-01 Kim Darrick S H L Methods for treatment of beta-amyloid protein-induced ocular disease
EP1254658B1 (en) * 2000-01-27 2008-09-24 Takara Bio Inc. Remedies for the treatment of nerve diorders
GEP20084442B (en) * 2001-12-14 2008-08-10 Council Scient Ind Res Compositions for the treatment of neurocerebrovascular disorders
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US7205011B2 (en) * 2003-11-14 2007-04-17 Board Of Regents, Acting For And On Behalf Of, University Of Arizona Anti-inflammatory activity of a specific turmeric extract
US20070003641A1 (en) 2005-06-15 2007-01-04 Kim Darrick S H Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease
EP1895849A4 (en) * 2005-06-15 2009-11-11 Darrick S H L Kim Methods for treatment of beta-amyloid protein-induced ocular disease
CA2663954A1 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Curcumin analogs, diagnostic methods and genetic markers for diagnosing and treating alzheimer's disease
WO2008042755A2 (en) 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2008131059A2 (en) * 2007-04-17 2008-10-30 Codman & Shurtleff, Inc. Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease
EP2416795B1 (en) 2009-04-09 2015-06-03 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
AU2010278711A1 (en) 2009-07-31 2012-02-23 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US9499462B2 (en) 2011-02-02 2016-11-22 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
EP4023294A1 (en) 2014-01-31 2022-07-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating alzheimer's disease
US9668999B2 (en) * 2014-04-23 2017-06-06 Semi Labs Limited Method for the treatment of hypercholesterolemia
CA3061787A1 (en) 2017-05-15 2018-11-22 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
CN110759878B (en) * 2019-10-29 2021-04-09 西安瑞联新材料股份有限公司 Synthetic method of phenyl tetrahydrofuran ether compound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266344A (en) * 1988-08-12 1993-11-30 Kabushiki Kaisha Kobe Seiko Sho Method for making tetrahydrocurcumin and a substance containing the antioxidative substance tetrahydrocurcumin
JPH07206669A (en) * 1994-01-14 1995-08-08 Nikken Food Kk Tyrosinase inhibitor
WO1997003674A1 (en) * 1995-07-14 1997-02-06 Sabinsa Corporation Bioprotectant composition, method of use and extraction process of curcuminoids
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
JPH11246398A (en) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd Prophylactic or therapeutic agent for disorder caused by increment of lipoperoxide in vivo
WO2000070949A1 (en) * 1999-05-20 2000-11-30 Heng Madalene C Y Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266344A (en) * 1988-08-12 1993-11-30 Kabushiki Kaisha Kobe Seiko Sho Method for making tetrahydrocurcumin and a substance containing the antioxidative substance tetrahydrocurcumin
JPH07206669A (en) * 1994-01-14 1995-08-08 Nikken Food Kk Tyrosinase inhibitor
WO1997003674A1 (en) * 1995-07-14 1997-02-06 Sabinsa Corporation Bioprotectant composition, method of use and extraction process of curcuminoids
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
JPH11246398A (en) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd Prophylactic or therapeutic agent for disorder caused by increment of lipoperoxide in vivo
WO2000070949A1 (en) * 1999-05-20 2000-11-30 Heng Madalene C Y Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ARTICO MARINO ET AL: "Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: Synthesis, biological evaluation, and molecular modeling.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 21, 8 October 1998 (1998-10-08), pages 3948 - 3960, XP001024902, ISSN: 0022-2623 *
CLOSTRE F: "Ginkgo biloba extract (EGb 761): A state of art at the dawn of the third millenium.", ANNALES PHARMACEUTIQUES FRANCAISES, vol. 57, no. SUPPL. 1, July 1999 (1999-07-01), pages 1S8 - 1S88, XP001032446, ISSN: 0003-4509 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, LIM G P ET AL: "Prevention of LTP deficits in Alzheimer transgenic HuAPPSw mice using a phenolic anti-oxidant/anti-inflammatory compound.", XP002180060, Database accession no. PREV200100121205 *
HUANG JING ET AL: "Novel biphenyl ether lignans from the rhizomes of Curcuma chuanyujin.", CHEMICAL & PHARMACEUTICAL BULLETIN (TOKYO), vol. 48, no. 8, 2000, pages 1228 - 1229, XP001024947, ISSN: 0009-2363 *
JUNG KI KYUNG ET AL: "Effects of curcumin on the microglial activation.", YAKHAK HOEJI, vol. 44, no. 5, October 2000 (2000-10-01), pages 448 - 454, XP001032424, ISSN: 0513-4234 *
KHOPDE SUJATA M ET AL: "Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue.", BIOPHYSICAL CHEMISTRY, vol. 80, no. 2, 9 August 1999 (1999-08-09), pages 85 - 91, XP001030178, ISSN: 0301-4622 *
KIM D S H L ET AL: "Inhibition of B-amyloid neurotoxicity in PC12 cells by CLZ-1, CLZ-2 and CLZ-3 isolated from Curcuma longa, Zingiberaceae: An approach toward a rational drug discovery of anti-Alzheimer disease.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, 28th Annual Meeting of the Society for Neuroscience, Part 2;Los Angeles, California, USA; November 7-12, 1998, pages 1457, XP001032467, ISSN: 0190-5295 *
KIM DARRICK S H L ET AL: "Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult.", NEUROSCIENCE LETTERS, vol. 303, no. 1, 27 April 2001 (2001-04-27), pages 57 - 61, XP001032445, ISSN: 0304-3940 *
KUNER PASCAL ET AL: "beta-Amyloid binds to p75NTR and activates NFkappaB in human neuroblastoma cells.", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 54, no. 6, 15 December 1998 (1998-12-15), pages 798 - 804, XP001032458, ISSN: 0360-4012 *
NAKAYAMA,TSUTOMU: "Strategy of chemical modification to free radical scavengers for suppression of hydrogen peroxide-induced cytotoxicity", FOOD FACTORS CANCER PREV., INT. CONF. (1997) MEEETING DATE 1995, 1997, pages 642 - 646, XP001032552 *
OSAWA TOSHIHIKO ET AL: "Antioxidative activity of tetrahydrocurcuminoids.", BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 59, no. 9, 1995, pages 1609 - 1612, XP001024945, ISSN: 0916-8451 *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 11 26 December 1995 (1995-12-26) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 14 22 December 1999 (1999-12-22) *
PRASAIN JEEVAN KUMAR ET AL: "Inhibitory effect of diarylheptanoids on nitric oxide production in activated murine macrophages.", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 21, no. 4, April 1998 (1998-04-01), pages 371 - 374, XP001024948, ISSN: 0918-6158 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 763.9, ISSN: 0190-5295 *
SOLIMAN KARAM F A ET AL: "In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds.", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 218, no. 4, 1998, pages 390 - 397, XP000867853, ISSN: 0037-9727 *
VENKATESHWARLU,VOBALABOINA: "Cyclo-oxygenase inhibitors from spices", INDIAN DRUGS, vol. 34, no. 8, 1997, pages 427 - 432, XP001032423 *

Also Published As

Publication number Publication date
AU2300001A (en) 2001-05-08
WO2001030335A2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
WO2001027119A3 (en) Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
EP1378240A3 (en) Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
NO324227B1 (en) Cyclopropyl-fused pyrrolidine-based compounds, pharmaceutical compositions and combinations containing them as well as the use thereof for the manufacture of medicaments for the treatment of diseases
WO2003080582A3 (en) Fredericamycin derivatives
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
HUP0101281A3 (en) Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
WO2004043341A3 (en) Treatment for hemorrhagic shock
WO2002028810A3 (en) Retinoids for the treatment of emphysema
DE60132851D1 (en) Medicines for the prevention, alleviation or treatment of hypertension
WO2001051044A3 (en) Substances for use in treating psoriasis
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
NO20010627L (en) Use of Gingko Biloba extracts for the preparation of a drug for the treatment of amyotrophic lateral sclerosis
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10111039

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP